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A b s t r a c t  
Ofloxacin (OFX) is a synthetic broad spectrum analog of second generation fluoroquinolone 
antibiotic. It is used for the treatment of urinary tract, prostate, skin, urinary and respiratory tract 
infections. Ornidazole (ORN) is a nitroimidazole derivative. It is used in the treatment of bacterial 
vaginosis, trichomoniasis, amoebiasis, giardiasis and infections due to anaerobic bacteria. These 
drugs are highly soluble in acidic media and precipitates in alkaline media thereby losing its 
solubility. Hence we attempted to develop a gastro retentive floating matrix type drug delivery 
system for Ofloxacin and Ornidazole in combined dosage form with hydroxyl propyl methyl cellulose 
(HPMC) K15M, HPMC K100M and polyethylene oxide 18NF (PEO). The physicochemical 
compatibility of the drug and the polymers was studied by infrared spectroscopy and differential 
scanning calorimetry. The results suggested no physicochemical incompatibility between the drug 
and the polymers. The prepared floating drug delivery systems were evaluated for physicochemical 
characteristics, mainly in vitro release and in vivo residence time by radiographic studies. The best 
formulation (F2) was selected based on in vitro release and physicochemical characteristics and 
used in vivo radiographic studies by incorporating BaSO4. These studies revealed that tablets 300 μ 
30 minutes in healthy human volunteers in fasting state and indicated that the gastric retention was 
increased by floating principle. By fitting the data into zero order, first order and Higuchi models, it 
was concluded that drug release from matrix tablets followed Higuchi model and the mechanism of 
drug release was diffusion mediated. Based on the physical evaluation, in vitro drug release and in 
vivo characteristics, it was concluded that for potential therapeutic use, suitable for the development 
of a floating drug delivery system of Ofloxacin and Ornidazole in combined dosage form. 
Keywords: Ofloxacin. Ornidazole.  Gastro retentive.  Floating tablets.  Hydroxy propyl methyl 
cellulose.   Poly ethylene oxide. 
 
Introduction 
Using current release technology, oral delivery for 24 h is possible 
for many drugs; however, the substance must be well absorbed 
throughout the whole gastrointestinal tract. A significant obstacle 
may arise if there is a narrow window for drug absorption in the 
gastrointestinal tract (GIT), if a stability problem exists in 
gastrointestinal fluids, or the drug is poorly soluble in the intestine 
or acts locally in the stomach. Thus, the real issue in the 
development of oral controlled release dosage forms is not just to 
prolong the delivery of the drugs for more than 12 h, but to prolong 
the presence of the dosage forms in the stomach or somewhere in 
the upper intestine until all of the drug is released over the desired 
period of time [1]. 
Controlled gastric retention of solid dosage forms may be achieved 
by the mechanisms of floating systems, swelling and expanding 
systems [2], bioadhesive systems, modified shape systems, high 
density systems or other delayed gastric emptying devices. The 
principle of buoyant preparation offers a residence time for the 
dosage form and sustained drug release [3]. 
The various buoyant preparations include microballoons [4, 5], 
granules, powders, capsules, tablets and laminated films [6]. 
Based on the mechanism of buoyancy, two distinctly different 
technologies, i.e., non-effervescent and effervescent systems have 
been utilized in the development of floating systems [7]. Non-
effervescent systems commonly use gel-forming or highly 
swellable cellulose type hydrocolloids, polysaccharides and matrix 
forming polymers such as polycarbonate, polyacrylate, 
polymethacrylate, and polystyrene. Effervescent systems utilize 
matrices prepared with swellable polymers such as methocel or 
chitosan and effervescent compounds, e.g., sodium bicarbonate 
and citric or tartaric acid [8, 9], or matrices containing chambers of 
liquid that gasify at body temperature.    
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Ofloxacin is a flouroquinolone, broad spectrum antibiotic, and is 
used in the treatment of urinary tract infections, prostatitis and 
gonorrhea. Ofloxacin is least absorbed from the lower part of the 
gastrointestinal tract and is better absorbed from the stomach. 
Ofloxacin is (μ) - 9- fluoro-2, 3- dihydro-3-methyl-10-(4-
methylpiperazine-1-yl) ă 7-oxo -7H- pyrido [1, 2, 3-de]- 1, 4-
benzoxazine-6-carboxylic acid [10]. Ornidazole is a nitroimidazole 
derivative. ORN  is used in treating Bacterial vaginosis, 
Trichomoniasis, Amoebiasis, Giardiasis (lambliasis) and infections 
due to anaerobic bacteria (infections such as septicemia, 
meningitis, peritonitis, postoperative wound infections, puerperal 
sepsis, septic abortion, and endomentritis, with demonstrated or 
suspected involvement of susceptible bacteria). OFX and ORN 
have site-specific absorption in the stomach region of the GI tract 
and precipitated when enter into intestinal regions. OFX and ORN 
have biological half-lifeÊs of 5-6hrs and 12hrs respectively and 
shows high solubility in acidic medium (gastric acid) and favors 
development of a gastro retentive formulation in combined dosage 
form. 
Experimental 
Materials 
OFX and ORN are generous gifts from Euro drugs, India. HPMC 
K15M and HPMC K100M were obtained from ISP, India.  PEO 
18NF was a generous gift sample from Dr. ReddyÊs Labs, India. 
Sodium bicarbonate, citric acid, talc and magnesium stearate 
(analytical grade) were purchased from S.D. Fine Chemicals Ltd. 
(Mumbai, India). All the other ingredients were of analytical grade. 
 Methods  
Solubility study 
Excess amount of OFX and ORN was placed in 0.1 N HCl, pH 4.5 
acetate buffer, phosphate buffer pH 6.8 and pH 7.4 respectively in 
order to determine its solubility. The samples were shaken for 24h 
at 37ĈC in a horizontal shaker (HS 501 Digital, IKA-Labortechnik, 
and Staufen, Germany). The supernatant was filtered and the 
filtrate was diluted with the appropriate dissolution medium and 
assayed by UV-spectrophotometer at 293nm and 317nm for OFX 
and ORN respectively. 
Simultaneous Spectrophotometric Estimation of OFX 
and ORN in tablet dosage form 
Two simple, sensitive, accurate and economical 
spectrophotometric methods were developed for the estimation of 
Ofloxacin and Ornidazole simultaneously in tablet dosage form. 
First method is based on the simultaneous equations and second 
method is based on Q-analysis (absorbance ratio method). 
Ofloxacin and Ornidazole show absorbance maxima at 294 nm and 
317 nm in N/2 acetic acid, respectively. 
 Development of combination of OFX and ORN necessitates 
developing and validating simple, rapid, accurate, 
spectrophotometric methods for simultaneous determination of 
Ofloxacin and Ornidazole in pharmaceutical dosage forms. 
Simultaneous Estimation of Ofloxacin and Ornidazole was carried 
out according to the methods described by Bhusari KP et al . 
Preparation of Single Unit Floating Matrix Tablets of 
OFX and ORN 
Accurately weighed quantities of polymer and MCC were taken in a 
mortar and mixed geometrically, to this required quantity of OFX 
and ORN was added and mixed slightly with pestle. Accurately 
weighed quantity of Sodium bicarbonate was taken separately in a 
mortar and powdered with pestle. The powder is passed through 
sieve no 40 and mixed with the drug blend which is also passed 
through sieve no # 40. The whole mixture was collected in a plastic 
bag and mixed for 3 minutes. To this Magnesium stearate was 
added and mixed for 5 minutes, later Talc was added and mixed 
for 2 minutes. The mixture equivalent to 900mg was compressed 
into tablets with 13 mm capsulated punches at a hardness of 6-7 
kg/cm2. 
The composition of various formulations was given in table1. 
Evaluation of physicochemical properties 
The  formulated  tablets  were  evaluated  for weight  variation, 
thickness, crushing  strength,  friability  and  content  uniformity. 
Weight variation 
Twenty  tablets  were  selected  at  random  and  the  average  
weight  of  the  tablets  was   determined.  The  weight  of  
individual  tablets  was  compared  with  the  average  weight. 
Thickness 
The thickness in millimeters (mm) was measured individually for 10 
pre weighed tablets by using a Vernier Caliperse. The average 
thickness and standard deviation were reported. 
Crushing strength and friability 
Crushing  strength  of  tablet  was  determined  by  Monsanto  
tester  (Campbell  Electronics, India)  hardness  tester.  Friability  
test  was  carried  out  using  Roche  friabilator  (Erection 
instrument  &  engineering,  Ahmedabad,  India).  Ten  tablets  
were  weighed  and  subjected  to the  combined  effect  of  attrition  
and  shock  by  utilizing  a  plastic  chamber.  The friabilator was 
operated for 100 revolutions (4 min, 25 rpm).  The tablets were 
dedusted and re-weighed to calculate the percentage of friability. 
Drug   content   uniformity 
Prepared tablets were accurately weighed and finely powdered by 
pestle in a mortar. A weighed portion of each powder equivalent to 
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mg of prepared tablet was transferred in to a volumetric flask and 
the drug was extracted with methanol as the solvent. The contents 
of the flask were  sonicated  for  10min  and  diluted  with  0.1 N 
HCl  as  the  solvent. The samples were analyzed   
spectrophotometrically at 294 nm and 317 nm for OFX and ORN 
respectively. 
In vitro buoyancy studies 
In vitro buoyancy studies were performed for all the twelve 
formulations as per the method described by Rosa et al [11]. The 
randomly selected tablets from each formulation were kept in a 
100ml beaker containing simulated gastric fluid, pH 1.2 as per 
USP. The time taken for the tablet to rise to the surface and float 
was taken as floating lag time (FLT). The duration of time the 
dosage form constantly remained on the surface of medium was 
determined as the total floating time (TFT). 
In vitro dissolution studies 
The release rate of OFX and ORN from floating tablets was 
determined using United States Pharmacopeia (USP) Dissolution 
Testing Apparatus 2 (paddle method). The dissolution test was 
performed using 900 ml of 0.1N hydrochloric acid, at 37 μ 0.5ĈC 
and 50 rpm. A sample (5 ml) of the solution was withdrawn from 
the dissolution apparatus at predetermined time intervals and the 
samples were replaced with fresh dissolution medium. The 
samples were filtered through a 0.45μ membrane filter and diluted 
to a suitable concentration with 0.1N hydrochloric acid. Absorbance 
of these solutions was measured at 293 nm for OFX and 317 nm 
for ORN using a UV/Visible double beam spectrophotometer 
((Elico, India). The percentage drug release was plotted against 
time to determine the release profile. 
In vivo X-Ray study 
The in vivo study was carried out by administering OFX and ORN 
floating matrix tablets to healthy human volunteers and monitoring 
them through a radiological method (X-ray study). To make the 
tablets X-ray opaque the incorporation of BaSO4 was necessary. 
The amount of the X-ray opaque material in these tablets was 
sufficient to ensure visibility by X-ray, but at the same time this 
amount of BaSO4 was low enough to enable tablets to float. Four 
healthy male subjects (mean age 27year; mean weight 60μ10kg) 
participate after giving informed   consent. The study approved by 
the Ethical Committee (UCPS, Kakatiya Univeristy, Warangal). The 
study was  conducted  by  administering  to  each  subject  one  
floating  tablet  on  fasted  state,  the subjects  fasted overnight 
then swallowed the floating tablets with 150ml water. After wards 
the subjects were not allowed to eat or drink [12].  In each subject 
the position of the floating tablet was monitored by X-ray 
photographs (Konica Minolta, Siemens, Karlsruhe, Germany) of the 
gastric region at determined time intervals. All X-ray films were 
taken in anterior positions. 
Stability studies 
Stability studies were carried out for optimized formulation F3 
according to the International Conference on Harmonization (ICH) 
guidelines. The samples were stored in closed HDPE bottles along 
with 1 g desiccant at 40 μ 2ĈC/75 μ 5% R.H. (Skylab Instruments 
and Engineering Pvt Ltd., Mumbai, India) for 3 months. Samples 
were withdrawn after 1, 2, and 3 months, and were evaluated for 
drug content and in vitro percentage drug release. 
Results and Discussion 
 Solubility study 
OFX and ORN is highly soluble in 0.1 N HCl, having quantitative 
solubility of 66.52 mg/ml and 10.68mg/ml of respectively. As pH 
increased solubility decreased drastically, i.e.  pH 4.5 acetate 
buffer (28.24 mg/ml of OFX and 6.17mg/ml of ORN);  pH 6.8 
phosphate buffer (7.18 mg/ml of OFX and 3.12mg/ml of ORN), and 
pH 7.4 phosphate buffer (0.25mg/ml of OFX and 1.63 mg/ml of 
ORN). It shows pH dependent solubility, highly soluble in acidic pH 
but poorly soluble in alkaline pH. Precipitation of the Ofloxacin 
occurs in intestine, which adversely affects the absorption in the 
lower sections of the intestine [13]. The result was show in figure 1. 
 
 
Figure 1: Solubilty of OFX and ORN in different mediums 
 
Simultaneous Spectrophotometric Estimation of OFX 
and ORN in tablet dosage form 
Simultaneous Estimation of Ofloxacin and Ornidazole was carried 
out according to the methods described by [14, 15] reported 
methods. 
First method is based on the simultaneous equations and second 
method is based on Q-analysis (absorbance ratio method). OFX 
and ORN show absorbance maxima at 294 nm and 317 nm in N/2 
acetic acid, respectively. The linearity was obtained in the 
concentration range of 2-10 øg/ml for Ofloxacin and 2-30 øg/ml for 
Ornidazole. In the first method, the concentrations of the drugs 
were determined by using simultaneous equations; and in the 
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second method, the concentrations of the drugs were determined 
by using ratio of absorbance at isoabsorptive point at 305nm. The 
results of analysis have been validated statistically and by recovery 
studies. 
 
Table 1: Composition (mg) of OFX and ORN floating tablets 
Formulation   HPMC K15M   HMPMC K100M   PEO 18NF MCC
F1                   90                       --                         --              115.5
   F2                   120                     --                          --                85.5   
   F3                  150                     --                          --                55.5 
   F4                   --                  60                --               145.5 
   F5            --                 90                 --             115.5 
   F6                  --              120                 --                85.5 
   F7            --                --                 120              85.5 
   F8                   --              --                 150              55.5 
   F9                   --               --                        180              25.5 
 
 All the tablets contain 200mg ofloxacin, 400mg ornidazole, 9 mg 
magnesium stearate and 9mg talc. HPMC ă hydroxy propyl methyl 
cellulose, MCC ă micro crystalline cellulose.  The average weight 
of all the formulations was 900mg. 
Evaluation of physical properties of pre-compressed 
granules 
The physical properties like Compressibility index (CI), Angle of 
repose and HaunserÊs ratio were calculated and tabulated in table 
2. The results of the physical properties of many of the blends were 
in the limits and comply with the standards. 
 
Table 2: Physical properties of final blend 
Formulation      CI                      Angle of             HaunserÊs
                                                      repose                    ratio 
F1                        12.1                      27.7o                 1.15 
F2                        15.8                      26.5o                 1.13 
F3                        12.5                      29.2o                 1.18 
F4                        15.4                      28.4o                 1.17 
F5                        12.3                      29.5o                 1.15 
F6                        11.2                      28.4o                         1.18 
F7                        13.7                      29.8o                 1.08 
F8                        12.2                      27.5o                 1.18 
F9                        14.8                      29.4o                 1.14 
Evaluation of physicochemical properties 
The tablets of OFX and ORN were prepared by direct compression 
technique using HPMC K15M, HPMC K100M and PEO 18NF.  
Magnesium stearate and talc were used as lubricant and glidant 
respectively. The data of physical parameters like thickness, drug 
content, weight variation, hardness, friability and in vitro buoyancy 
properties, of all the formulations is enclosed in table 3.  All the 
parameters lie within the limits. The average weight of the tablets 
was 900mg and the weight variation for every batch was less than 
μ 5%.  The hardness was maintained as 6.5 to 7 kg/cm2 in all the 
formulations. The friability of all the formulations falls in the 
acceptable limit. The drug content in the range of 96.54μ2.5% to 
98.56μ2.5% for ORN and 97.67μ2.6% to 99.65μ1.4% for OFX. 
In vitro buoyancy studies 
The prepared floating matrix tablets buoyant for 12 h with a lag 
time of less than 95 seconds.   The optimized concentration of the 
gas-generating agent (sodium bicarbonate) contributed to the 
buoyancy of all tablets. Buoyancy results of floating matrix tablets 
are shown in table 3. 
In vitro dissolution studies 
An ideal controlled release system should be able to release the 
drug immediately to attain the therapeutic level at a faster rate and 
maintain this drug level for a prolonged period of time. In vitro drug 
release studies revealed that the release of ofloxacin and 
ornidazole from different formulations varies with characteristics 
and composition of matrix forming polymers as shown in figure 2a.  
 
 
Figure 2a: In vitro dissolution of ofloxacin and ornidazole from 
HPMC K15M floating matrix tablets  
 
The release rate of ofloxacin from formulations F1, F3 and 
ornidazole F1, F2, and F3 was decreased with increasing 
concentration of HPMC K15M.  The release rate of ofloxacin and 
ornidazole from F2 formulations were found to be 98.64 μ1.34% 
and 73.31μ1.74% in 12h respectively. Upon increasing the 
concentration of polymer the release rate of ofloxacin from 
formulations F1 and F3 were found to be 91.14μ1.27% in 8h and 
81.19μ2.01% in 12h and ornidazole were found to be 82.34μ0.97% 
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and 64.76μ1.84% in 12h from the observations of physical 
parameters the formulation F2 exhibit controlled and prolonged 
release of drugs. 
In vitro dissolution study of formulations F4, F5 and F6 prepared 
with HPMC K100M were done in 0.1N HCl and the percent of 
ofloxacin and ornidazole drug release from formulations F5 and F6 
was 96.89μ2.12%, 81.96μ1.73% and 72.81μ1.64%, 62.53μ2.21% 
in 12 h respectively. Formulation F5 and F6 unable to sustain the 
drug release desired period of time. This is because of change in 
polymer concentrations used in these formulations compared to 
K15M. Formulations F6 failed to meet the desired drug release 
profile. Formulation F5 obtained the desired drug release profile 
and floated with a lag time of 95 sec, for these reasons it was 
considered as the best formulation among all the four formulations. 
The release profile from all these formulations were followed 
diffusion controlled release complying with higher correlation 
coefficient values of Higuchi. Formulation F5 was considered as 
best formulation among all the four formulations as it showed good 
buoyancy properties (floating lag time: 95 sec & floating time >12 
hrs) (figure 2b) 
 
 
Figure 2b: In vitro dissolution of ofloxacin and ornidazole from HPMC K100M floating matrix tablets 
 
and sustained the drug release for desired period of time (12 
hrs).In vitro dissolution study of formulations F7 to F9 were also  
 
done in 0.1N HCl and the percent drug released was calculated 
(figure 2c). These three formulations prepared with PEO  
 
 
 
Figure 2c: In vitro dissolution of ofloxacin and ornidazole from PEO 18NF floating matrix tablets 
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Table 3: Physical Evaluation parameters: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a=20, b=6, c=20) 
 
18NF. The polymer should have the lower viscosity than the 
methocel polymers. The results indicated that higher viscosity 
grade of polymer concentrations drug release was retarded greatly. 
Formulations   F7 and F9 release the ofloxacin in 6h and 10h 
respectively. This was ascertained due to the insufficiency of the 
polymer to form a rigid gel barrier around the tablet ultimately 
leading to loss of matrix integrity. Increasing the polymer level (F8 
and F9 formulations) resulted in sustaining the release rate of 
ofloxacin upto 12h. The release rate of ornidazole from 
formulations was decreased with increased concentration of 
polymer in 12h. Among these formulations F8 should release the 
96.43μ2.04% % and 68.76μ2.16% of ofloxacin and ornidazole 
respectively with a floating lag time of 48seconds.   
Data of the in vitro release was fit into kinetic models to explain the 
release kinetics from floating tablets [16]. The kinetic models used 
were zero-order equation, first-order equation, and Higuchi [17, 18] 
and Korsemeyer-Peppas models. The cumulative amount of the 
drug released from the tablets, when plotted against square-root of 
time the release profiles of drug seemed to follow Higuchi model as 
it was evidenced by correlation coefficients (r2 = 0.98 to 0.99) 
better than zero order (r2 = 0.93 to 0.98) and first order (r2 = 0.52 
to 0.57). The data was further treated as per the following equation 
for Korsemeyer-Peppas models [19, 20]   
                                     Mt/M¥ = K.tn    
Where,   Mt/M¥is the fractional release of the drug, Mt is the amount 
released at time t, M¥ is the total amount of drug contained in the 
matrix tablet, t is the release time, K is a kinetic constant, and n is 
the diffusional release exponent indicative of the operating release 
mechanism. The n values obtained were below 0.5 indicative of 
Fickian diffusion (table 4).  
 
Table 4:  Regression coefficient (r2) values of different kinetic models of OFX and ORN floating matrix tablets 
Code     Zero order (r2)        First order (r2)        Higuchi (r2)              Korsmeyer (r2)              n value 
           OFX       ORN         OFX       ORN         OFX        ORN         OFX        ORN            OFX      ORN 
    F1     0.945      0.897        0.526      0.523      0.988        0.912       0.923      0.912          0.509        0.536 
   F2      0.968      0.923       0.559      0.526      0.999        0.991       0.931       0.920           0.541      0.533 
   F3      0.98        0.96         0.605      0.588      0.976        0.981       0.904       0.892          0.293       0.382 
   F4      0.928      0.915       0.476      0.45        0.986         0.973      0.902       0.917          0.422       0.389 
   F5      0.92        0.931       0.466      0.539      0.991         0.990      0.963       0.932          0.501       0.539 
   F6      0.928      0.979       0.484      0.633      0.997         0.974      0.946       0.903          0.538       0.562 
   F7      0.933      0.802       0.534      0.352      0.948         0.958      0.932       0.953          0.716       0.536 
   F8      0.976      0.956       0.361      0.504      0.925         0.983      0.972       0.913          0.522       0.518 
   F9      0.906      0.917       0.421      0.462      0.992         0.985      0.921       0.937          0.529       0.513 
 
Comparing the two different grades of methocel (K15M and 
K100M) and PEO 18NF, it was found that low-viscosity grade 
methocel K15M provided better-controlled release characteristics 
with excellent drug release and in vitro buoyancy. Formulation F2 
selected has optimized from the observations of physical 
Formulation     Weight                Hardness    Thickness     Friability     Drug Content (%)c         Floating         Floating       
                         variation (mg)a   (kg/cm2)b           (mm)                                   ORN       OFX          lag time (sec)   time (hr)     
 F1                  903μ4.3              6.8μ0.5         6.7μ0.06        0.23       98.5μ2.5     99.6μ1.4        81μ2.1                  >12 
F2                   902μ4.5              7μ0.3            6.8μ0.03        0.48       98.2μ3.6     99.1μ1.9       79μ1.9                   >12 
F3                   903μ3.7              6.5μ0.5         6.7μ0.04        0.51       97.9μ2.9     98.6μ1.4       76μ2.8                  >12 
F4                   902μ4.7              6.8μ0.5         6.6μ0.05        0.35       97.4μ2.7     99.5μ2.4       99μ3.2                  >12 
F5                   901μ3.9              7μ0.2            6.5μ0.25        0.38       97.6μ2.4     98.6μ2.1       95μ2.8                   >12 
F6                   903μ4.5              6.8μ0.5         6.5μ0.04        0.41       97.3μ3.4     98.4μ3.4      105μ2.4                  >12 
F7                   901μ4.6              7μ0.3            6.5μ0.07        0.25       97.4μ3.5     98.5μ2.5       40μ01.9                >12 
F8                   900μ4.8              7.2μ0.1         6.4μ0.04        0.28       97.9μ3.7     99.3μ3.1        42μ1.8                 >12 
F9                   905μ4.6              6.8μ0.2         6.6μ0.06        0.39       96.4μ2.5     97.7μ2.6        48μ2.5                 >12 
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